Onco-nephrology: Renal toxicities of chemotherapeutic agents

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 10, 2012, Pages 1713-1721

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; INTERFERON; METHOTREXATE; PANITUMUMAB; PEMETREXED;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CARCINOMA; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CRYOGLOBULINEMIA; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; EDEMA; FANCONI RENOTUBULAR SYNDROME; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HEMATURIA; HEMORRHAGIC CYSTITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DAMAGE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PANCREAS CARCINOMA; PROTEINURIA; SARCOMA; SIDE EFFECT; TESTIS CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY; KIDNEY DISEASES; MEDICAL ONCOLOGY; NEOPLASMS; NEPHROLOGY; PROGNOSIS; RISK FACTORS;

EID: 84867253360     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02780312     Document Type: Article

References (45)

1. Sahni V, Choudhury D, Ahmed Z: Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 5: 450-462, 2009
2. Perazella MA, Moeckel GW: Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30: 570-581, 2010
3. Finkel KW, Foringer JR: Renal disease in patientswith cancer. Nat Clin Pract Nephrol 3: 669-678, 2007
4. Lameire NH, Flombaum CD, Moreau D, Ronco C: Acute renal failure in cancer patients. Ann Med 37: 13-25, 2005
5. de Jonge MJA, Verweij J: Renal toxicities of chemotherapy. Semin Oncol 33: 68-73, 2006
6. Humphreys BD, Soiffer RJ, Magee CC: Renal failure associated with cancer and its treatment: An update. J Am Soc Nephrol 16: 151-161, 2005
7. Evenepoel P: Acute toxic renal failure. Best Pract Res Clin Anaesthesiol 18: 37-52, 2004
8. Singh NP, Ganguli A, Prakash A: Drug-induced kidney diseases. J Assoc Physicians India 51: 970-979, 2003
9. Guo X, Nzerue C: How to prevent, recognize, and treat druginduced nephrotoxicity. Cleve Clin J Med 69: 289-297, 2002
10. Jerkić M, Vojvodić S, López-Novoa JM: The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction. Int Urol Nephrol 32: 539-547, 2001
11. Perazella MA: Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 4: 1275-1283, 2009
12. Harty L, Johnson K, Power A: Race and ethnicity in the era of emerging pharmacogenomics. J Clin Pharmacol 46: 405-407, 2006
13. Ciarimboli G, Koepsell H, Iordanova M, Gorboulev V, Dürner B, Lang D, Edemir B, Schröter R, Van Le T, Schlatter E: Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 16: 1562-1570, 2005
14. Ulrich CM, Bigler J, Potter JD: Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140, 2006
15. Lang F: Regulating renal drug elimination? J Am Soc Nephrol 16: 1535-1536, 2005
16. Enomoto A, Endou H: Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9: 195-205, 2005
17. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484, 2005
18. Cummings BS, Schnellmann RG: Pathophysiology of nephrotoxic cell injury. In: Diseases of the Kidney and Urogenital Tract, edited by Schrier RW, Philadelphia, PA, Lippincott Williams & Wilkinson, 2001, pp 1071-1136
19. Kaloyanides GJ, Bosmans J-L, DeBroe ME: Antibiotic and immunosuppression-related renal failure. In: Diseases of the Kidney and Urogenital Tract, edited by SchrierRW, Philadelphia, PA, Lippincott Williams & Wilkinson, 2001, pp 1137-1174
20. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G: Cytochrome P450 3A and 2B6 in the developing kidney: Implications for ifosfamide nephrotoxicity. Pediatr Nephrol 20: 872-885, 2005
21. Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 122: 322-328, 2009
22. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S: Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68: 1207-1213, 2011
23. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605-12608, 2003
24. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008
25. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G: Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203-218, 2007
26. Glezerman IG, Kris MG, Miller V, Seshan S, Flombaum CD: Gemcitabine nephrotoxicity and hemolytic uremic syndrome: Report of 29 cases from a single institution. Clin Nephrol 71: 130-139, 2009
27. Markowitz GS, Nasr SH, Stokes MB, D'Agati VD: Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 607-615, 2010
28. Colovic M, Jurisic V, Jankovic G, Jovanovic D, Nikolic LJ, Dimitrijevic J: Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: Case report and review of literature. J Clin Pathol 59: 879-881, 2006
29. Pabla N, Dong Z: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008
30. Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M: Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharmacol Sci 100: 65-72, 2006
31. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL: Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66: 2202-2213, 2004
32. Ramesh G, Reeves WB: TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285: F610-F618, 2003
33. Morgan KP, Buie LW, Savage SW: The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother 46: 276-281, 2012
34. Zamlauski-Tucker MJ, Morris ME, Springate JE: Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 129: 170-175, 1994
35. Ciarimboli G, Holle SK, Vollenbröcker B, Hagos Y, Reuter S, Burckhardt G, Bierer S, Herrmann E, Pavenstädt H, Rossi R, Kleta R, Schlatter E: Newclues for nephrotoxicity induced by ifosfamide: Preferential renal uptake via the human organic cation transporter 2. Mol Pharm 8: 270-279, 2011
36. Glezerman IG, Pietanza MC, Miller V, Seshan SV: Kidney tubular toxicity of maintenance pemetrexed therapy. AmJ Kidney Dis 58: 817-820, 2011
37. Glaudemans B, Knoers NV, Hoenderop JG, Bindels RJ: New molecular players facilitating Mg(21) reabsorption in the distal convoluted tubule. Kidney Int 77: 17-22, 2010
38. Schrag D, Chung KY, Flombaum C, Saltz L: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97: 1221-1224, 2005
39. Fakih MG, Wilding G, Lombardo J: Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer. 6: 152-156, 2006
40. Saif MW: Management of hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol 6: 243-248, 2008
41. Dietrich A, Chubanov V, Gudermann T: Renal TRPathies. J Am Soc Nephrol 21: 736-744, 2010
42. Cao Y, Liao C, Tan A, Liu L, Gao F: Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy 56: 459-465, 2010
43. Perazella MA: Crystal-induced acute renal failure. Am JMed 106: 459-465, 1999
44. Pinheiro FV, Pimentel VC, De Bona KS, Scola G, Salvador M, Funchal C, Moretto MB: Decrease of adenosine deaminase activity and increase of the lipid peroxidation after acute methotrexate treatment in young rats: protective effects of grape seed extract. Cell Biochem Funct 28: 89-94, 2010
45. Patterson DM, Lee SM: Glucarbidase following high-dose methotrexate: Update on development. Expert Opin Biol Ther 10: 105-111, 2010